Table 5.
Expression of immunohistochemical markers in categories of histological grade for primary hepatocellular carcinoma cases n (%)
| IHC marker | Cut-off | Cases/valid samples | P value | ||
| Grades 1 + 2 | Grade 3 | Grade 4 | |||
| EGFR overexpression | ≥ 200/3001 | 14 (67)a | 12 (27) | 3 (30) | 0.008a |
| Ki67 | ≥ 0.1% | 6 (30)a | 31 (74) | 8 (80) | 0.002a |
| K19 | > 1% | 0 (0) | 7 (17) | 5 (45)a | 0.005a |
| Vimentin | > 0/300 | 0 (0) | 3 (7) | 1 (9) | 0.465 |
| Caspase 3 loss | ≤ 10/300 | 3 (15) | 16 (38) | 8 (73)a | 0.006a |
| Cyclin D1 | > 0.1% | 4 (20) | 9 (21) | 3 (30) | 0.847 |
| mTOR expression | ≥ 100/3001 | 7 (37) | 17 (45) | 1 (10) | 0.134 |
| MET expression | ≥ 100/3001 | 8 (42)a | 6 (14) | 0 (0) | 0.012a |
| ERK1 overexpression | ≥ 200/3001 | 0 (0) | 8 (20) | 2 (18) | 0.081 |
| ERK2 overexpression | ≥ 200/3001 | 1 (5) | 6 (14) | 3 (30) | 0.148 |
| p53 | ≥ 10% | 5 (28) | 16 (42) | 7 (64) | 0.164 |
| Beta-catenin, membrane | ≥ 100/3001 | 13 (65) | 25 (64) | 4 (40) | 0.343 |
| Beta-catenin, nucleus | 2 or 3+ | 0 (0) | 1 (3) | 1 (10) | 0.352 |
1
Score value.
a
P < 0.05 (outliers in pairwise test). EGFR: Epidermal growth factor receptor; ERK: Extracellular signaling-related kinase; HCC: Hepatocellular carcinoma; IHC: Immunohistochemistry; MET: MET receptor tyrosine kinase; mTOR: Mechanistic target of rapamycin.